Search

Roivant Sciences Ltd

Închisă

SectorSănătate

41 0.44

Rezumat

Modificarea prețului

24h

Curent

Minim

40.36

Maxim

41.58

Indicatori cheie

By Trading Economics

Venit

-646M

-291M

Vânzări

-1.1M

1.4M

EPS

-0.45

Marjă de profit

-20,152.982

Angajați

721

EBITDA

-743M

-288M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+11.62% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

1.2B

25B

Deschiderea anterioară

40.56

Închiderea anterioară

41

Sentimentul știrilor

By Acuity

50%

50%

112 / 339 Clasament în Healthcare

Roivant Sciences Ltd Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 sept. 2026, 20:13 UTC

Shares of Roivant Sciences are lower in after-market hours, reflecting a notable decline since Monday's close, despite remaining above the 20-day moving average.

11 sept. 2026, 20:13 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, amid broader market concerns over potential Federal Reserve interest rate hikes following recent inflation data.

10 sept. 2026, 23:31 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

9 sept. 2026, 23:06 UTC

Roivant Sciences Ltd shares are higher in after-market hours, maintaining a narrow trading range since Wednesday's close and staying above the 20-day moving average.

8 sept. 2026, 23:06 UTC

Event
News

Roivant Sciences Ltd shares are lower in after-market hours despite positive Phase 2 trial results for mosliciguat targeting pulmonary hypertension.

4 sept. 2026, 22:51 UTC

Correlated Moves

Roivant Sciences Ltd shares are lower in after-market trading, reflecting broader market declines and negative sentiment in the biotech sector.

2 sept. 2026, 20:08 UTC

Roivant Sciences Ltd shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

1 sept. 2026, 19:36 UTC

Roivant Sciences Ltd is trading lower amid broader market sentiment and rising oil prices. The stock remains below its 20-day moving average.

31 aug. 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-hours trading, showing modest gains since Monday's close amid rising oil prices and geopolitical tensions.

29 aug. 2026, 00:01 UTC

Roivant Sciences Ltd shares are higher in after-market hours, reflecting notable activity despite a retracement from earlier gains. No specific news was identified.

28 aug. 2026, 23:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Friday's close, despite no specific news identified.

27 aug. 2026, 23:02 UTC

Roivant Sciences Ltd. shares are higher in after-market trading, remaining above the 20-day moving average despite earlier fluctuations during the session.

26 aug. 2026, 22:41 UTC

Roivant Sciences Ltd is trading higher in after-market hours, reflecting broader market gains. The asset has closed higher for three consecutive sessions.

25 aug. 2026, 23:16 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, continuing a steady decline since Tuesday's close, though still above the 20-day moving average.

24 aug. 2026, 23:01 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, retracing from an earlier session high while remaining above the 20-day moving average.

21 aug. 2026, 19:31 UTC

Roivant Sciences is declining in Friday's session, with no specific news identified. The stock has seen unusually high trading volume today.

20 aug. 2026, 23:21 UTC

Roivant Sciences Ltd. shares are lower in after-market trading amid broader market pressures, including rising bond yields and concerns over high borrowing costs.

19 aug. 2026, 23:26 UTC

Roivant Sciences Ltd is seeing upward momentum in after-market trading, recovering from a prior dip and nearing the upper end of its one-month trading range.

18 aug. 2026, 23:01 UTC

Roivant Sciences Ltd shares are lower in after-market trading, declining notably after Tuesday's close amid rising U.S. Treasury yields and inflation concerns.

17 aug. 2026, 19:36 UTC

Roivant Sciences shares are roughly flat amid broader market declines. The bond market faces upward pressure on yields due to inflation concerns.

14 aug. 2026, 19:26 UTC

Roivant Sciences Ltd. remains near unchanged amid no specific news, fluctuating around flat levels during Friday's session. It is 4.29% above its 20-day moving average.

13 aug. 2026, 19:36 UTC

Roivant Sciences Ltd is trading modestly higher amid broader market dynamics. Initial jobless claims rose above expectations, indicating potential softness in the labor market.

12 aug. 2026, 22:11 UTC

Roivant Sciences shares are higher in after-market trading, driven by a positive market reaction to the July Consumer Price Index report.

11 aug. 2026, 21:01 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing recent declines amid broader market volatility linked to U.S.-Iran relations.

10 aug. 2026, 23:02 UTC

Roivant Sciences Ltd shares are higher in after-market hours, trading above their 20-day moving average and near the upper end of their one-month range.

7 aug. 2026, 20:02 UTC

Event
News

Roivant Sciences Ltd shares are higher as HC Wainwright maintains a Buy rating and raises the price target to $41 amid positive developments in its product pipeline.

6 aug. 2026, 20:03 UTC

News
Event

Roivant Sciences reported a net loss of $290.6 million in Q1, exceeding expectations. Shares are higher despite pulling back from session highs earlier.

5 aug. 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Wednesday's close. The stock is positioned above its 20-day moving average.

4 aug. 2026, 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

3 aug. 2026, 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

Comparație

Modificare preț

Roivant Sciences Ltd Așteptări

Obiectiv de preț

By TipRanks

11.62% sus

Prognoză pe 12 luni

Medie 45.563 USD  11.62%

Maxim 55 USD

Minim 37.5 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRoivant Sciences Ltd - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

7

Cumpărare

1

Păstrare

0

Vânzare

Sentiment

By Acuity

112 / 339 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat